Free Trial
NASDAQ:BGLC

BioNexus Gene Lab Q1 2025 Earnings Results & Report

BioNexus Gene Lab logo
$1.27 +0.02 (+1.98%)
As of 10/9/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BioNexus Gene Lab reported Q1 2025 earnings on May 15, 2025. The company reported EPS of -$0.03.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
After Market Closes

BioNexus Gene Lab EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BioNexus Gene Lab Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

BioNexus Gene Lab Q1 2025 Earnings FAQ

BioNexus Gene Lab (NASDAQ:BGLC) reported earnings of -$0.03 per share for Q1 2025. The report was announced on Thursday, May 15, 2025.

BioNexus Gene Lab Earnings Headlines

BioNexus (NASDAQ: BGLC) signs Malaysia AI licence as closing stays pending
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.tc pixel
See More BioNexus Gene Lab Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioNexus Gene Lab? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioNexus Gene Lab and other key companies, straight to your email.

About BioNexus Gene Lab

BioNexus Gene Lab (NASDAQ:BGLC) is a biotechnology company focused on molecular diagnostics and health-related testing. The company develops and commercializes non-invasive, blood-based diagnostic technologies designed to identify genetic and molecular indicators associated with disease, with an emphasis on supporting earlier detection and personalized healthcare.

Its business activities include gene analysis, molecular diagnostic testing and the development of RNA-based biomarker applications. BioNexus Gene Lab has also described activities involving health and wellness products and services, complementing its diagnostic technology initiatives.

The company’s operations have included a presence in Malaysia, where it has pursued laboratory, diagnostic and biotechnology activities. Publicly available information about its product portfolio, geographic reach and current leadership is limited, so additional details may change as the company continues to develop and commercialize its technologies.

View BioNexus Gene Lab Profile